炎症性肠病与肠道微生态关系的研究进展
|
摘要
<正>炎症性肠病(inflammatory bowel diseases,IBD)包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn’s disease,CD),主要表现为反复发作的腹泻、腹痛、黏液血便,在发达国家是常见的消化道疾病,发病率可达到30/100 000,但是随着工业化的发展,生活节奏加快,在发展中国家亦常见,中国IBD在广州、武汉、大庆、成都、西安的发病率分别为1.8/100 000、2. 8/100 000、12. 6/100 000、3/100 000、6/100 000,并且逐年迅速上升[1]。目前认为IBD发病
引文
[1]Ng WK,Wong SH,Ng SC.Changing epidemiological trends of inflammatory bowel disease in Asia[J].Intestinal Research,2016,14(2):111-119.
[2]Gensonlen T,Iyer SS,Kasper DL,et al.How colonization by microbiota in early life shapes the immune system[J].Science,2016,352(6285):539-544.
[3]Liu TC,Stappenbeck TS.Genetics and Pathogenesis of Inflammatory Bowel Disease[J].Annu Rev Pathol,2016,11:127-148.
[4]石鼎,李兰娟.人体微生态与感染性疾病的研究进展[J].生命科学,2017,29(7):624-629.
[5]武艳芳,陈平.肠道微生态在炎症性肠病发病中的作用及治疗前景[J].医学综述,2017,23(23):4688-4693.
[6]Fyderek K,Strus M,Kowalska Duplaga K,et al.Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease[J].World Journal of Gastroenterol,2009,15(42):5287-5294.
[7]Ricanek P,Lothe SM,Frye SA,et al.Gut bacterial profile inpatients newly diagnosed with treatment-na6ve Crohn’s disease[J].Clinical&Experimental Gastroenterol,2012,5:173-186.
[8]Walker AW,Sanderson JD,Churcher C,et al.Highthroughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease[J].BMC Microbiology,2011,11:7.
[9]Matsuoka K,Kanai T.The gut microbiota and inflammatory bowel disease[J].Seminars in Immunopathology,2015,37(1):47-55.
[10]Kataoka K.The intestinal microbiota and its role in human health and disease[J].J Med Invest,2015,63(1-2):27-37.
[11]曹卉,王伟,卢锐锋,等.活动期与缓解期溃疡性结肠炎患者黏膜主要菌群研究[J].中华实验外科杂志,2016,33(4):1109-1112.
[12]张婷,陈烨,王中秋,等.炎症性肠病患者肠道菌群结构的变化及其与炎性指标的关系[J].南方医科大学学报,2013,33(10):1474-1477.
[13]Wang W,Chen L,Zhou R,et al.Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease[J].Journal of Clinical Microbiology,2014,52(2):398-406.
[14]蔚晓霞,刘占举,胡艺,等.炎症性肠病患者的肠道菌群分布与血清TNF-α与IL-6水平的相关性[J].现代生物医学进展,2017,17(16):3076-3078.
[15]张艳丽,刘新风,于秀娟,等.炎症性肠病患者肠道菌群变化及其与炎性因子的相关性[J].山东医药,2015,55(10):79-80.
[16]叶雅丽,闫李侠.肠道菌群分析及粪便炎性标志物检测在炎症性肠病活动度评估中的作用[J].中国微生态学杂志,2018,30(3):312-316,326.
[17]Wang ZK,Yang YS,Stefka AT,et al.Review article:fungal microbiota and digestive diseases[J].Alimentary Pharmacology&Therapeutics,2014,39(8):751-766.
[18]Gouba N,Drancourt M.Digestive tract mycobiota:a source of infection[J].Médecine Et Maladies Infectieuses,2015,45(1-2):9-16.
[19]Mukherjee PK,Sendid B,Hoarau G,et al.Mycobiota in gastrointestinal diseases[J].Nature Reviews Astroenterology&Hepatology,2015,12(2):77-87.
[20]Richard ML,Lamas B,Liguori G,et al.Gut Fungal Microbiota:The Yin and Yang of Inflammatory Bowel Disease[J].Inflammatory Bowel Diseases,2015,21(3):656-665.
[21]Li Q,Wang C,Tang C,et al.Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn’s disease[J].Journal of Clinical Gastroenterology,2014,48(6):513-523.
[22]何琴,戴伟,唐春,等.克罗恩病人肠黏膜炎性区域真菌菌群组成变化研究[J].肠外与肠内营养,2017,24(6):369-373.
[23]钱家鸣,栾子键.微生态制剂在炎症性肠病中的应用[J].中国实用内科杂志,2016,36(9):733-735.
[24]王霄腾,戴金锋,吕宾.益生菌对炎症性肠病诱导和维持缓解疗效的meta分析[J].胃肠病学,2015,20(1):29-35.
[25]Shen J,Zuo ZX,Mao AP.Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis,Crohn’s disease,and pouchitis:meta-analysis of randomized controlled trials[J].Inflamm Bowel Dis,2014,20(1):21-35.
[26]薛爱娟,黄瑛.益生菌在儿童炎症性肠病的应用[J].中国实用儿科杂志,2017,32(2):101-103.
[27]笪荣峰,刘云华,江应平,等.益生菌联合美沙拉嗪对炎症性肠病患者临床治疗效果、不良反应及生活质量的影响[J].结直肠肛门外科,2016,22(S2):135-136.
[28]程灿昌,李国华,杜国平,等.美沙拉嗪联合益生菌治疗炎症性肠病的临床疗效分析[J].现代诊断与治疗,2016,27(10):1809-1810.
[29]尹明明,施嫣红,沈蓉蓉,等.益生菌改善炎症性肠病患者的临床疗效和肠屏障功能观察[J].中国微生态学杂志,2017,29(4):427-430.
[30]Kao D,Hotte N,Gillevet P,et al.Fecal microbiota transplantation inducing remission in Crohn’s colitis and the associated changes in fecal microbial profile[J].Journal of Clinical Gastroenterology,2014,48(7):625-628.
[31]Cui B,Li P,Xu L,et al.Step-up fecal microbiota transplantation strategy:a pilot study for steroid-dependent ulcerative colitis[J].Journal of Translational Medicine,2015,13:298.
[32]Tian Z,Liu J,Liao M,et al.Beneficial Effects of Fecal Microbiota Transplantation on Ulcerative Colitis in Mice[J].Digestive Diseases&Sciences,2016,61(8):2262-2271.
[33]Sha S,Liang J,Chen M,et al.Systematic review:faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children[J].Alimentary Pharmacology&Therapeutics,2014,39(10):1003-1032.
[34]Moayyedi P,Surette MG,Kim PT,et al.Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized,Controlled Trial[J].Gastroenterology,2015,149(1):102-109.
[35]Rossen NG,Fuentes S,van der Spek MJ,et al.Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis[J].Gastroenterology,2015,149(1):110-118.e4.
[36]Zhang FM,Wang HG,Wang M,et al.Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease[J].World Journal of Gastroenterology,2013,19(41):7213-7216.
[37]张慧,李潘,徐海娥,等.粪菌移植联合肠内营养治疗克罗恩病的初步研究[J].中国医学工程,2016,24(12):1-4.
[2]Gensonlen T,Iyer SS,Kasper DL,et al.How colonization by microbiota in early life shapes the immune system[J].Science,2016,352(6285):539-544.
[3]Liu TC,Stappenbeck TS.Genetics and Pathogenesis of Inflammatory Bowel Disease[J].Annu Rev Pathol,2016,11:127-148.
[4]石鼎,李兰娟.人体微生态与感染性疾病的研究进展[J].生命科学,2017,29(7):624-629.
[5]武艳芳,陈平.肠道微生态在炎症性肠病发病中的作用及治疗前景[J].医学综述,2017,23(23):4688-4693.
[6]Fyderek K,Strus M,Kowalska Duplaga K,et al.Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease[J].World Journal of Gastroenterol,2009,15(42):5287-5294.
[7]Ricanek P,Lothe SM,Frye SA,et al.Gut bacterial profile inpatients newly diagnosed with treatment-na6ve Crohn’s disease[J].Clinical&Experimental Gastroenterol,2012,5:173-186.
[8]Walker AW,Sanderson JD,Churcher C,et al.Highthroughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease[J].BMC Microbiology,2011,11:7.
[9]Matsuoka K,Kanai T.The gut microbiota and inflammatory bowel disease[J].Seminars in Immunopathology,2015,37(1):47-55.
[10]Kataoka K.The intestinal microbiota and its role in human health and disease[J].J Med Invest,2015,63(1-2):27-37.
[11]曹卉,王伟,卢锐锋,等.活动期与缓解期溃疡性结肠炎患者黏膜主要菌群研究[J].中华实验外科杂志,2016,33(4):1109-1112.
[12]张婷,陈烨,王中秋,等.炎症性肠病患者肠道菌群结构的变化及其与炎性指标的关系[J].南方医科大学学报,2013,33(10):1474-1477.
[13]Wang W,Chen L,Zhou R,et al.Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease[J].Journal of Clinical Microbiology,2014,52(2):398-406.
[14]蔚晓霞,刘占举,胡艺,等.炎症性肠病患者的肠道菌群分布与血清TNF-α与IL-6水平的相关性[J].现代生物医学进展,2017,17(16):3076-3078.
[15]张艳丽,刘新风,于秀娟,等.炎症性肠病患者肠道菌群变化及其与炎性因子的相关性[J].山东医药,2015,55(10):79-80.
[16]叶雅丽,闫李侠.肠道菌群分析及粪便炎性标志物检测在炎症性肠病活动度评估中的作用[J].中国微生态学杂志,2018,30(3):312-316,326.
[17]Wang ZK,Yang YS,Stefka AT,et al.Review article:fungal microbiota and digestive diseases[J].Alimentary Pharmacology&Therapeutics,2014,39(8):751-766.
[18]Gouba N,Drancourt M.Digestive tract mycobiota:a source of infection[J].Médecine Et Maladies Infectieuses,2015,45(1-2):9-16.
[19]Mukherjee PK,Sendid B,Hoarau G,et al.Mycobiota in gastrointestinal diseases[J].Nature Reviews Astroenterology&Hepatology,2015,12(2):77-87.
[20]Richard ML,Lamas B,Liguori G,et al.Gut Fungal Microbiota:The Yin and Yang of Inflammatory Bowel Disease[J].Inflammatory Bowel Diseases,2015,21(3):656-665.
[21]Li Q,Wang C,Tang C,et al.Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn’s disease[J].Journal of Clinical Gastroenterology,2014,48(6):513-523.
[22]何琴,戴伟,唐春,等.克罗恩病人肠黏膜炎性区域真菌菌群组成变化研究[J].肠外与肠内营养,2017,24(6):369-373.
[23]钱家鸣,栾子键.微生态制剂在炎症性肠病中的应用[J].中国实用内科杂志,2016,36(9):733-735.
[24]王霄腾,戴金锋,吕宾.益生菌对炎症性肠病诱导和维持缓解疗效的meta分析[J].胃肠病学,2015,20(1):29-35.
[25]Shen J,Zuo ZX,Mao AP.Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis,Crohn’s disease,and pouchitis:meta-analysis of randomized controlled trials[J].Inflamm Bowel Dis,2014,20(1):21-35.
[26]薛爱娟,黄瑛.益生菌在儿童炎症性肠病的应用[J].中国实用儿科杂志,2017,32(2):101-103.
[27]笪荣峰,刘云华,江应平,等.益生菌联合美沙拉嗪对炎症性肠病患者临床治疗效果、不良反应及生活质量的影响[J].结直肠肛门外科,2016,22(S2):135-136.
[28]程灿昌,李国华,杜国平,等.美沙拉嗪联合益生菌治疗炎症性肠病的临床疗效分析[J].现代诊断与治疗,2016,27(10):1809-1810.
[29]尹明明,施嫣红,沈蓉蓉,等.益生菌改善炎症性肠病患者的临床疗效和肠屏障功能观察[J].中国微生态学杂志,2017,29(4):427-430.
[30]Kao D,Hotte N,Gillevet P,et al.Fecal microbiota transplantation inducing remission in Crohn’s colitis and the associated changes in fecal microbial profile[J].Journal of Clinical Gastroenterology,2014,48(7):625-628.
[31]Cui B,Li P,Xu L,et al.Step-up fecal microbiota transplantation strategy:a pilot study for steroid-dependent ulcerative colitis[J].Journal of Translational Medicine,2015,13:298.
[32]Tian Z,Liu J,Liao M,et al.Beneficial Effects of Fecal Microbiota Transplantation on Ulcerative Colitis in Mice[J].Digestive Diseases&Sciences,2016,61(8):2262-2271.
[33]Sha S,Liang J,Chen M,et al.Systematic review:faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children[J].Alimentary Pharmacology&Therapeutics,2014,39(10):1003-1032.
[34]Moayyedi P,Surette MG,Kim PT,et al.Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized,Controlled Trial[J].Gastroenterology,2015,149(1):102-109.
[35]Rossen NG,Fuentes S,van der Spek MJ,et al.Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis[J].Gastroenterology,2015,149(1):110-118.e4.
[36]Zhang FM,Wang HG,Wang M,et al.Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease[J].World Journal of Gastroenterology,2013,19(41):7213-7216.
[37]张慧,李潘,徐海娥,等.粪菌移植联合肠内营养治疗克罗恩病的初步研究[J].中国医学工程,2016,24(12):1-4.